Demand for HIV prevention injection exceeds supply in Uganda, Kenya and Malawi
By the AFREEQUE newsroom, based on The Observer

Lenacapavir, a twice-yearly HIV prevention injection, is in short supply in Uganda, Kenya and Malawi, according to health officials attending a regional webinar. In Uganda, the Ministry of Health is reporting more new users, including people who had previously declined other forms of prevention, according to The Observer.
Demand for lenacapavir, a long-acting HIV prevention injection administered twice a year, exceeds available stocks in Uganda, Kenya and Malawi, according to health officials from the three countries who attended a regional webinar reported by The Observer.
In Uganda, the Ministry of Health’s HIV prevention coordinator, Peter Mudiope, said that people who had declined other forms of pre-exposure prophylaxis (PrEP) are now requesting the injection. When it was launched on 17 April, the pilot site had only 20 doses, which were used up immediately, even though some needed to be reserved for the following six months. The country now has 103 facilities offering lenacapavir and is expecting new doses in December, which will be prioritised for areas with the highest numbers of people on oral PrEP. The aim is to increase this number to 300 by December 2026.
Warren Mitchell, executive director of the AVAC organisation, said the three countries had experienced similar situations. Kenneth Mwehonge, executive director of HEPS Uganda, called for investment in community structures responsible for providing information, tackling stigma and misinformation, and directing interested people to services, beyond awareness-raising campaigns alone. Officials urged against generating demand that health systems cannot meet.





